{"id":53417,"date":"2023-01-30T16:02:45","date_gmt":"2023-01-30T15:02:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-naloxone-market-report-2022-to-2030-parenteral-segment-dominated-the-formulation-market-researchandmarkets-com\/"},"modified":"2023-01-30T16:02:45","modified_gmt":"2023-01-30T15:02:45","slug":"global-naloxone-market-report-2022-to-2030-parenteral-segment-dominated-the-formulation-market-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-naloxone-market-report-2022-to-2030-parenteral-segment-dominated-the-formulation-market-researchandmarkets-com\/","title":{"rendered":"Global Naloxone Market Report 2022 to 2030: Parenteral Segment Dominated the Formulation Market – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Naloxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.\n<\/p>\n

\nNaloxone is an opioid antagonist designed to rapidly reverse opioid overdose. Naloxone can restore the normal respiration of a person whose breathing has stopped or slowed down due to opioid or heroin overdose. Currently, opioid abuse is one of the foremost causes of drug overdose and is a leading cause of death globally. However, it is more common in North America and Europe.\n<\/p>\n

\nThe Increasing Prevalence of Opioid Overdoses Remains as The Most Impactful Driver<\/strong>\n<\/p>\n

\nThe increasing prevalence of opioid overdoses is expected to drive the growth of the naloxone market. An increasing incidence of opioid drug abuse in both the developed and developing worlds remains the key driver for the market growth of the naloxone market.\n<\/p>\n

\nOn average, more than 130 people in America die each day from an opioid overdose. Opioids are a class of drugs that include even prescription drugs such as oxycodone, fentanyl, morphine, and hydrocodone. It also includes illegal drugs such as heroin or drugs sold as heroin. The use of opioids for chronic pain management has increased worldwide. This has further increased the non-medical use of opioids due to their addictive characteristics. This is expected to drive the growth of the naloxone market.\n<\/p>\n

\nThe Parenteral Segment Dominated the Formulation Market<\/strong>\n<\/p>\n

\nBased on the formulation\/route of administration, the naloxone market is categorized as parenteral, intranasal, and sublingual. The parenteral segment contributed highest to the market revenues.\n<\/p>\n

\nHospitals still remain the key resort when individuals are overdosed, and parenteral remains the key preferred administration method among healthcare professionals. The sublingual route stands second followed by the parenteral route.\n<\/p>\n

\n0.4mg\/ml Most Preferred Dosage<\/strong>\n<\/p>\n

\nBased on dosage\/strength, the naloxone market is segmented into 0.4mg\/ml, 1mg\/1ml, 0.4mg\/0.4ml and 4 mg\/0.1 ml. 0.4mg\/ml led the market revenues in 2021. However, there is only a minor difference between 4mg\/0.1 ml and the other dosages, which stand second in terms of 2021 revenues. The most recommended injections are dosed as 0.4mg at the start of the treatment.\n<\/p>\n

\nAPAC to Grow Fastest During the Forecast Period<\/strong>\n<\/p>\n

\nAfter scrutiny of the naloxone market, regional trends, market sizes, and the overall growth paired with the latest and anticipated events, Asia Pacific is observed to be the most attractive region for the naloxone market owing to a swift growth in the uptake of medicines to prevent surging death rates. The U.S. holds the largest market owing to having the largest number of substance addicts vis a vis awareness for available options to reverse the ill effects of an overdose. Latin America is followed by North America.\n<\/p>\n

\nCollaborations – Key Strategy among Top Market Players<\/strong>\n<\/p>\n

\nIndivior remains at the top position with respect to product portfolio and business strength. Currently Indivior hold maximum number of products directly and indirectly related to naloxone, for instance, Suboxone, Sublocade and Subutex. Soboxne patent has expired and hence generic products are being introduced in the market. The key strategies followed by the company includes collaborations to understand the key market segments.\n<\/p>\n

\nHistorical & Forecast Period<\/strong>\n<\/p>\n

\nThis study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.\n<\/p>\n

\nKey questions answered in this report<\/strong>\n<\/p>\n